welcome
ScienceBlog.com

ScienceBlog.com

Health

Health

HIV Drug Shows Promise for Diabetes Vision Loss

ScienceBlog.com
Summary
Nutrition label

88% Informative

Drug lamivudine improved vision in patients with diabetic macular edema.

Current treatments involve monthly eye injections that carry risks of infection and retinal detachment.

Current anti-VEGF treatments like aflibercept and ranibizumab rank among the top five drugs in Medicare spending, with monthly costs reaching $ 2,000 per injection.

The trial was small and lasted only eight weeks , following patients for a relatively short period.

The researchers found encouraging signs that lamivudine’s benefits extended beyond the typical four-week window when most DME improvement occurs.

Vision continued improving during weeks five through eight , suggesting sustained therapeutic effects.

Whether this HIV drug will ultimately transform diabetes care remains to be seen, but early evidence suggests we may be witnessing the beginning of a new chapter.